fda decision on tirzepatide What Is Used for? Approved and Potential Uses FDA says the tirzepatide weight-loss

For a middle-aged patient with creeping weight gain and a family history of heart disease, starting oral semaglutide can be the decisive factor that prevents a future heart attack

NDC: 00169-4130-13

GLP-1RAs excel at inducing short-term weight loss by imposing a powerful external satiety signal, whereas postbiotics may contribute to stabilizing the endogenous signaling environment that governs appetite regulation and metabolic adaptation ( Adipose tissue plasticity and thermogenic capacity: BAT, browning, and the physiological ceiling in humans The discovery of metabolically active BAT in adult humans raised expectations that obesity therapies might meaningfully increase energy expenditure through thermogenesis ( In humans, however, BAT mass is limited, heterogeneous, and reduced in obesity, and even maximal activation contributes only modestly to total energy expenditure ( Importantly, the physiological ceiling on BAT-mediated thermogenesis implies that increasing energy expenditure is unlikely to offset the metabolic adaptation associated with rapid weight loss

Soroosh, A

JAMA Netw Open 2020;3:e1919099

Teach clients about building sustainable habits and making informed decisions that contribute to long-term health